Page last updated: 2024-11-12

nelumal a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nelumal A: aromatase inhibitor from Ligularia nelumbifolia; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
LigulariagenusA genus of ornamental plants in the family ASTERACEAE, often found near water.[MeSH]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]

Cross-References

ID SourceID
PubMed CID11175348
CHEMBL ID464705
SCHEMBL ID18265465
MeSH IDM000597945

Synonyms (6)

Synonym
CHEMBL464705
nelumal a
geranyloxy sinapyl aldehyde
(e)-3-[3,5-dimethoxy-4-[[(e)-3,7-dimethyl-2,6-octadienyl]oxy]phenyl]propenal
SCHEMBL18265465
(e)-3-[4-[(2e)-3,7-dimethylocta-2,6-dienoxy]-3,5-dimethoxyphenyl]prop-2-enal
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID659714Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 25 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID607600Induction of human U373 cell death assessed as morphological changes at MTT assay-related IC50 after 72 hrs by quantitative video microscopy2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID659715Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 50 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID607595Cytotoxicity against human A549 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID607594Cytotoxicity against human OE21 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID607593Cytotoxicity against human U373 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID659712Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 5 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID335516Cytotoxicity against human HL60 cells by SRB assay2002Journal of natural products, Jun, Volume: 65, Issue:6
Syntheses of two cytotoxic sinapyl alcohol derivatives and isolation of four new related compounds from Ligularia nelumbifolia.
AID659716Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 100 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID607601Cytotoxicity against human U373 cells assessed as growth inhibition at MTT assay-related IC50 by quantitative video microscopy relative to control2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID335515Cytotoxicity against human A549 cells by SRB assay2002Journal of natural products, Jun, Volume: 65, Issue:6
Syntheses of two cytotoxic sinapyl alcohol derivatives and isolation of four new related compounds from Ligularia nelumbifolia.
AID607598Cytotoxicity against human LoVo cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID659710Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 0.1 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID607597Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID659711Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 1 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID659713Agonist activity at human farnesoid X receptor expressed in human HepG2 cells at 10 uM after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
AID335517Cytotoxicity against human KB cells after 72 hrs2002Journal of natural products, Jun, Volume: 65, Issue:6
Syntheses of two cytotoxic sinapyl alcohol derivatives and isolation of four new related compounds from Ligularia nelumbifolia.
AID607596Cytotoxicity against human PC3 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID659717Agonist activity at human farnesoid X receptor expressed in human HepG2 cells after 24 hrs by dual-luciferase assay relative to control2012Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.20 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]